PolyPid (PYPD) vs Neuronetics (STIM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
PolyPid (PYPD) has outperformed Neuronetics (STIM) over the past year, gaining 42.9% versus a loss of 27.9%. Over five years, STIM leads with a -56.0% price change compared with -97.8% for PYPD. Neuronetics is the larger company by market cap ($163.1 million vs $99.5 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PYPD | STIM |
|---|---|---|
| Share price | $4.90 | $2.14 |
| Market cap | $99.53M | $163.06M |
| 1-day change | -1.01% | -1.38% |
| YTD return | +12.90% | +55.07% |
| 1-year return | +42.86% | -27.95% |
| 5-year return | -97.83% | -55.97% |
| EPS (TTM) | $-1.44 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.73 | $3.44 |
| 52-week low | $3.06 | $0.80 |
| Distance from 52-week high | -14.49% | -37.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +139.80% | +168.69% |
| Average volume | 176.73K | 2.07M |
| Shares outstanding | 20.31M | 76.20M |
| Employees | 69 | 658 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYPD has outperformed STIM by 70.8 percentage points over the past year.
- The two companies sit in different sectors: PolyPid in Healthcare and Neuronetics in Health Care.
About PolyPid
PYPD stock →PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Healthcare · Biotechnology · 69 employees
About Neuronetics
STIM stock →Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 658 employees
PYPD vs STIM FAQ
Which is bigger, PolyPid or Neuronetics?
Neuronetics (STIM) is larger, with a market capitalization of $163.06M compared with $99.53M for PolyPid (PYPD).
Which stock has performed better over the past year, PYPD or STIM?
PYPD returned +42.86% over the past 12 months, compared with -27.95% for STIM (price return, excluding dividends). Past performance does not predict future results.
Are PolyPid and Neuronetics in the same industry?
No. PolyPid is in the Healthcare sector, while Neuronetics is in Health Care.